Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 689.6m

Basilea Pharmaceutica Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

David Veitch

Chief executive officer

CHF 1.9m

Total compensation

CEO salary percentage33.33%
CEO tenure8yrs
CEO ownership0.2%
Management average tenure8.3yrs
Board average tenure3.5yrs

Recent management updates

Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being

Apr 10
Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Recent updates

Basilea Pharmaceutica (VTX:BSLN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Aug 29
Basilea Pharmaceutica (VTX:BSLN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Emerging Markets And Drug Resistance Will Drive Global Expansion

Key Takeaways Expanding global sales of key anti-infective drugs and successful commercialization partnerships are driving top-line growth and increased royalty income. Strategic pipeline development, acquisitions, and a partnership-driven model support profit growth, regulatory momentum, and future market expansion.

Benign Growth For Basilea Pharmaceutica AG (VTX:BSLN) Underpins Its Share Price

Jul 29
Benign Growth For Basilea Pharmaceutica AG (VTX:BSLN) Underpins Its Share Price

Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being

Apr 10
Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being

Estimating The Intrinsic Value Of Basilea Pharmaceutica AG (VTX:BSLN)

Apr 04
Estimating The Intrinsic Value Of Basilea Pharmaceutica AG (VTX:BSLN)

There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings

Feb 26
There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings

Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt

Feb 20
Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt

Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Apr 18
Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now

Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Sep 20
Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?

Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Feb 17
Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)

Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

Jul 01
Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)

CEO Compensation Analysis

How has David Veitch's remuneration changed compared to Basilea Pharmaceutica's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025CHF 2mCHF 635k

CHF 40m

Sep 30 2025n/an/a

CHF 56m

Jun 30 2025n/an/a

CHF 73m

Mar 31 2025n/an/a

CHF 75m

Dec 31 2024CHF 2mCHF 624k

CHF 78m

Sep 30 2024n/an/a

CHF 38m

Jun 30 2024n/an/a

-CHF 652k

Mar 31 2024n/an/a

CHF 5m

Dec 31 2023CHF 2mCHF 611k

CHF 10m

Sep 30 2023n/an/a

CHF 33m

Jun 30 2023n/an/a

CHF 56m

Mar 31 2023n/an/a

CHF 34m

Dec 31 2022CHF 2mCHF 599k

CHF 12m

Sep 30 2022n/an/a

CHF 6m

Jun 30 2022n/an/a

CHF 851k

Mar 31 2022n/an/a

-CHF 3m

Dec 31 2021CHF 2mCHF 594k

-CHF 7m

Sep 30 2021n/an/a

-CHF 26m

Jun 30 2021n/an/a

-CHF 45m

Mar 31 2021n/an/a

-CHF 30m

Dec 31 2020CHF 1mCHF 589k

-CHF 15m

Sep 30 2020n/an/a

-CHF 6m

Jun 30 2020n/an/a

CHF 3m

Mar 31 2020n/an/a

-CHF 10m

Dec 31 2019CHF 1mCHF 583k

-CHF 22m

Compensation vs Market: David's total compensation ($USD2.44M) is above average for companies of similar size in the Swiss market ($USD1.37M).

Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.

CEO

David Veitch (60 yo)

8yrs
Tenure
CHF 1,903,815
Compensation

Mr. David Veitch has been the Chief Executive Officer of Basilea Pharmaceutica Ltd. since April 19, 2018 and Basilea Pharmaceutica International Ltd., since September 1, 2014. Mr. Veitch joined Basilea in...

Leadership Team

NamePositionTenureCompensationOwnership
David Veitch
Chief Executive Officer8yrsCHF 1.90m0.21%
CHF 1.4m
Adesh Kaul
Chief Financial Officer7yrsno data0.13%
CHF 909.1k
Gerrit Hauck
Chief Technology Officer7.9yrsno data0.080%
CHF 548.7k
Laurenz Kellenberger
Chief Scientific Officer17.3yrsno data0.070%
CHF 481.4k
Marc Engelhardt
Chief Medical Officer8.3yrsno data0.13%
CHF 901.0k
Peer Schroder
Head of Corporate Communications & Investor Relationsno datano datano data
Damian Heller
General Counsel & Corporate Secretary8.7yrsno datano data
Andreas Kumin
Head of Corporate Developmentno datano datano data
Ursula Eberhardt
Head of Global Human Resources9.3yrsno datano data
Mark Jones
Head of Global Affairs8.3yrsno datano data
Peter Bielmeier
Head of Global Quality Management3.6yrsno datano data
Mohammed Benghezal
Head of Biologyno datano datano data
8.3yrs
Average Tenure
59yo
Average Age

Experienced Management: BSLN's management team is seasoned and experienced (8.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Nicole Onetto
Independent Non-Executive Director9yrsCHF 192.13k0.014%
CHF 95.2k
Leonard Kruimer
Independent Non-Executive Director4yrsCHF 192.13k0.0078%
CHF 53.9k
Naseem Amin
Independent Directorno datano datano data
Alf Gunnar Nicklasson
Independent Non-Executive Director13yrsCHF 211.75k0.022%
CHF 154.0k
Carole Sable
Independent Non-Executive Director3yrsCHF 192.13kno data
Thomas Werner
Independent Non-Executive Vice-Chairman14.4yrsCHF 219.60k0.012%
CHF 84.7k
Anne Michelle Whitaker
Independent Directorno datano datano data
Stephan Schindler
Independent Non-Executive Chairman1yrCHF 336.90kno data
3.5yrs
Average Tenure
65.5yo
Average Age

Experienced Board: BSLN's board of directors are considered experienced (3.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/19 01:33
End of Day Share Price 2026/04/17 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Basilea Pharmaceutica AG is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Thomas MeyerBaader Helvea Equity Research
Leonildo DelgadoBaader Helvea Equity Research